Project Grant R01CA309123
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $670K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charlottesville, VA 22904, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Virginia Polytechnic Institute & State University a $395,248 Project Grant effective August 11, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct proof-of-concept and feasibility testing of episodic future thinking (EFT) interventions for smoking cessation. This two-year project, concluding July 31, 2027, will develop and evaluate both generalized EFT and cancer-specific EFT approaches...
- The National Institutes of Health National Cancer Institute awarded The Medical University of South Carolina $586,018 on July 10, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a three-arm clinical trial testing augmented doses of nicotine replacement therapy for individuals who use both combustible cigarettes and e-cigarettes and wish to quit both products. The trial will randomize dual-use participants to receive behavioral support combined with...
- The National Cancer Institute awarded Washington State University $560,858 on July 21, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a randomized controlled trial evaluating a remote telehealth intervention combining varenicline and app-based contingency management for rural smokers with alcohol use disorder. The trial will enroll 192 rural smokers seeking smoking cessation treatment and living with an alcohol use disorder. Participants will be...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $177,500 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to adapt and evaluate a community navigator-led tobacco cessation intervention for cancer patients experiencing food insecurity. The project, titled QUITTRACK, addresses the elevated rate of tobacco dependence among food-insecure cancer patients—44 percent of cancer patients who smoke experience food insecurity,...
- The National Cancer Institute awarded the Board of Regents of the University of Nebraska, through its University of Nebraska Medical Center division, $948,630 under the Cancer Cause and Prevention Research program (CFDA 93.393) on August 1, 2026, for a naturalistic cohort study examining the real-world effectiveness of smoking cessation aids in US adults. The project will conduct a longitudinal survey study using the Understanding America Study, a nationally representative panel of 20,000 US...
- The National Cancer Institute, an operating division of the Department of Health and Human Services, awarded Chapman University $649,603 on June 15, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct the TRAQ-TO-QUIT smoking cessation intervention study. The research combines three evidence-based approaches into a multilevel intervention: pediatrician-initiated brief advice and referral to cessation services; novel behavioral tele-counseling to guide smokers...
- The National Cancer Institute of the National Institutes of Health awarded the University of Southern California $426,828 on July 6, 2026, through the Cancer Cause and Prevention Research program (CFDA 93.393) to test regulatory strategies promoting e-cigarette cessation among young adults. The University of Southern California will conduct a study using a simulated vape shop experimental laboratory space ("The Puff Point") to evaluate two innovative policy interventions designed to...
- Grant Award Summary Duke University received a $906,306 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) awarded September 11, 2025, with completion targeted for August 31, 2028. The award funds development and testing of a telehealth-delivered, cue-based treatment intervention designed to promote smoking cessation among people who smoke lightly (PSLI), defined as those smoking 10 cigarettes per day or fewer. Building...
- The National Cancer Institute awarded the University of Virginia $514,563 under the Cancer Treatment Research program (CFDA 93.395) on September 1, 2026, to develop adaptive randomization designs for identifying optimal dose combinations in early-phase clinical trials applicable to both oncology and non-oncology agents. The project targets the practical implementation of FDA Project Optimus principles by creating flexible early-stage trial designs that balance treating study participants with...
- The National Cancer Institute awarded $415,257 to the University of Virginia on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop a comprehensive intervention addressing financial toxicity among cancer survivors and caregivers. The award funds a two-year project (July 1, 2026 through June 30, 2028) performed in Charlottesville, Virginia. The intervention will address all domains of financial toxicity—material burden, psychosocial distress, and coping...